February 28, 2020 / 11:34 AM / a month ago

BRIEF-Verastem Oncology Sees Strategic Realignment To Reduce Its Operating Expenses By About 40% For 2020

Feb 28 (Reuters) - Verastem Inc:

* VERASTEM ONCOLOGY ANNOUNCES NEW STRATEGIC DIRECTION TO ADVANCE ITS CLINICAL DEVELOPMENT PROGRAMS

* VERASTEM INC- SEES STRATEGIC REALIGNMENT TO REDUCE ITS OPERATING EXPENSES BY APPROXIMATELY 40% FOR 2020 COMPARED TO 2019

* VERASTEM INC - GENERATED PRELIMINARY UNAUDITED COPIKTRA NET PRODUCT REVENUE OF $3.6 MILLION FOR Q4 OF 2019, COMPARED TO $4.0 MILLION FOR Q3 OF 2019

* VERASTEM -WILL BE REDUCING RESOURCES DIRECTED TO PROMOTION AND SALE OF COPIKTRA , INCLUDING REDUCING SIZE OF SALESFORCE & NON-CORE CLINICAL RESEARCH Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below